{"id":"W3107140765","doi":"10.2967/jnumed.120.249029","title":"First Experiences with <sup>177</sup>Lu-PSMA Therapy in Combination with Pembrolizumab or After Pretreatment with Olaparib in Single Patients","year":2020,"lang":"en","type":"article","venue":"Journal of Nuclear Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Pembrolizumab; Olaparib; Medicine; Prostate cancer; Internal medicine; Oncology; Immunotherapy; Urology; Combination therapy; Prostate-specific antigen; Cancer; DNA; Polymerase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008138174,0.0007966551,0.0006859622,0.0001983861,0.0009197004,0.0006939956,0.0004660946,0.001015793,0.001931924],"category_scores_gemma":[0.001511179,0.0003076184,0.0008631792,0.0002639807,0.000463086,0.0006014807,0.0006030403,0.001492684,0.0006736651],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006216988,"about_ca_system_score_gemma":0.0004001132,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005362209,"about_ca_topic_score_gemma":0.0009382336,"domain_scores_codex":[0.9994708,0.0001988909,0.0000436241,0.0001144673,0.00005341664,0.0001189141],"domain_scores_gemma":[0.9991385,0.0002056596,0.0001512385,0.0001083202,0.0000484027,0.0003478881],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"case_report","study_design_scores_codex":[0.02084726,0.01939049,0.1494161,0.001595682,0.002890689,0.1052232,0.006568353,0.004566847,0.1123035,0.002685309,0.01287628,0.5616363],"study_design_scores_gemma":[0.006863296,0.1957063,0.1315404,0.0004088301,0.002058646,0.4052378,0.001361469,0.005592763,0.1343538,0.002053655,0.1145044,0.0003187253],"study_design_candidate":"case_report","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9742634,0.009996712,0.00513505,0.001268793,0.0001782639,0.0003017354,0.0001292224,0.0001907579,0.008536009],"genre_scores_gemma":[0.9925709,0.002299418,0.001704224,0.001111014,0.0002352007,0.0001103407,0.0001725686,0.00003599937,0.001760147],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001931924,"threshold_uncertainty_score":0.006462991,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02740922171934527,"score_gpt":0.2722952437973554,"score_spread":0.2448860220780102,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}